Please Wait.....
Report
Anticoagulant Reversal Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 135 Pages I Mordor Intelligence
Anticoagulant Reversal Drugs Market Analysis
The anticoagulant reversal drugs market size reached USD 1.51 billion in 2025 and is forecast to attain USD 2.69 billion by 2030, advancing at a 12.15% CAGR. Growth stems from greater adoption of direct oral anticoagulants (DOACs), an expanding elderly population, and faster regulatory approvals that shorten time-to-market for new reversal agents. Hospitals are widening DOAC-first protocols, which in turn heighten demand for rapid, specific reversal solutions. Rising use of AI-driven coagulation diagnostics is improving bleed detection and guiding earlier intervention, while on-shored plasma collection strengthens prothrombin complex concentrate (PCC) supply resilience. Competitive momentum intensified after Novartis secured abelacimab, a Factor XI inhibitor linked to 67% bleeding reduction compared with rivaroxaban, signalling a shift toward next-generation agents that could further reposition the anticoagulant reversal drugs market.
Global Anticoagulant Reversal Drugs Market Trends and Insights
Aging Population & Rising Prevalence of Blood-Borne Disorders
Growing life expectancy pushes atrial fibrillation prevalence to 9% among those over 80 years, increasing chronic exposure to anticoagulants and heightening reversal needs. Hospitals now embed geriatric-specific anticoagulation pathways that guarantee availability of multiple reversal options for elderly patients who often cycle through varied regimens. This demographic shift elevates the strategic value of stocking both broad-spectrum PCCs and targeted agents for DOAC-associated bleeds.
Accelerated US FDA/EMA Fast-Track Approvals
Regulators prioritize unmet urgency over traditional timelines; andexanet alfa advanced under accelerated approval, while MK-2060 gained Fast Track status in 2025, cutting typical development windows from 8-12 years to roughly 5-7 years. The European Medicines Agency now accepts surrogate endpoints and real-world evidence for life-saving reversal therapies, allowing firms with robust data packages to capture early-mover advantage.
High Cost of Novel Agents
Andexanet alfa costs USD 25,000-50,000 per treatment, a 10-25 fold premium over PCCs, prompting insurers to impose prior-authorization hurdles and emerging-market hospitals to restrict use. Economic models still debate net savings relative to reduced ICU stays, slowing adoption despite proven anti-Factor Xa reversal efficacy.
Other drivers and restraints analyzed in the detailed report include:
Hospital Adoption of DOAC-First Protocols Driving Demand for Reversal Agents / AI-Driven Coagulation Diagnostics Enabling Earlier Reversal Intervention / Thrombo-Embolic Risk & Black-Box Warnings /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Prothrombin complex concentrates generated the largest revenue in 2024, holding 39.35% of anticoagulant reversal drugs market share, buoyed by decades of clinical familiarity and recent approval of Balfaxar that ensures diversified domestic supply. Hospitals value PCC versatility across warfarin and certain off-label DOAC emergencies, cementing a stable baseline within the anticoagulant reversal drugs market.
Recombinant decoy proteins such as andexanet alfa headline the fastest-growing cohort with a projected 14.25% CAGR through 2030. Their precise neutralization of Factor Xa inhibitors positions them as the contemporary standard for specific DOAC reversal, albeit at a high cost. Monoclonal antibodies could follow a similar trajectory once abelacimab concludes late-stage trials, potentially reshaping competitive hierarchies inside the anticoagulant reversal drugs market.
Life-threatening hemorrhage accounted for 47.53% of the anticoagulant reversal drugs market size in 2024, as rapid antidote access remains vital for intracranial, gastrointestinal, and trauma-related bleeds. Emergency clinicians prioritize agents with short onset and proven hemostatic efficacy, sustaining robust utilization across stroke centers and trauma networks.
Elective surgery posts the highest 13.85% CAGR, reflecting wider adoption of prophylactic reversal in planned cardiac or neurological procedures where anticoagulant continuation elevates bleed risk. Protocolized peri-operative management increases predictable demand and encourages manufacturers to explore longer-acting formulations suitable for scheduled care, thereby adding depth to the anticoagulant reversal drugs market.
The Anticoagulant Reversal Drugs Market Report is Segmented by Drug Class (Prothrombin Complex Concentrates, Coagulation Factors, Phytonadione, and More), Indication (Life-Threatening Bleeding, and More), Route of Administration (Intravenous Bolus/Infusion, and Sub-Cutaneous), End User (Hospital Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America delivered 41.82% of global revenue in 2024, supported by FDA-guided protocols that favor specific reversal agents and strong reimbursement for premium-priced products. Level 1 trauma systems and comprehensive stroke networks uphold steady consumption, while Health Canada's 2024 clearance of Ondexxya widened continental access.
Asia-Pacific is projected to outpace all regions at 14.51% CAGR. Japan's approval of Ondexxya, rising DOAC usage in China and India, and cardiovascular disease prevalence across urbanizing economies are converging forces expanding the anticoagulant reversal drugs market. National databases such as South Korea's highlight major bleeding incidence that reinforces policy mandates for antidote availability.
Europe remains stable with coordinated EMA guidance and mature plasma supply chains backing PCC production. Germany, the United Kingdom, and France adopt cost-effectiveness metrics, compelling manufacturers to pair clinical evidence with economic value propositions. Middle East & Africa trail but represent white-space potential as tertiary-care capacity grows, albeit tempered by pricing constraints that currently limit widespread penetration of next-generation agents.
List of Companies Covered in this Report:
Alexion Pharmaceuticals Inc. / CSL Behring / Pfizer / AstraZeneca / Octapharma / Boehringer Ingelheim / Fresenius / Bausch Health / Amneal Pharmaceuticals / Ferring Pharmaceuticals / Baxter / Johnson&Johnson / Perosphere Pharma / Nichi-Iko Pharma / Grifols / Sanquin Blood Supply Foundation / Octava Pharma USA (Balfaxar) /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging Population & Rising Prevalence Of Blood-Borne Disorders
4.2.2 Accelerated US FDA/EMA Fast-Track Approvals
4.2.3 Hospital Adoption Of DOAC-First Protocols Driving Demand For Reversal Agents
4.2.4 AI-Driven Coagulation Diagnostics Enabling Earlier Reversal Intervention
4.2.5 Supply-Chain On-Shoring Of Plasma-Derived Pccs
4.3 Market Restraints
4.3.1 High Cost Of Novel Agents
4.3.2 Thrombo-Embolic Risk & Black-Box Warnings
4.3.3 Competition From Point-Of-Care Coagulation Devices Reducing Drug Need
4.4 Porter's Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitutes
4.4.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Drug Class
5.1.1 Prothrombin Complex Concentrates
5.1.2 Coagulation Factors
5.1.3 Monoclonal Antibodies
5.1.4 Recombinant Decoy Proteins
5.1.5 Phytonadione
5.1.6 Other Classes
5.2 By Indication
5.2.1 Life-threatening Bleeding
5.2.2 Emergency Surgery
5.2.3 Elective Surgery
5.3 By Route of Administration
5.3.1 Intravenous Bolus/Infusion
5.3.2 Sub-cutaneous
5.4 By End User
5.4.1 Hospital Pharmacies
5.4.2 Emergency Departments/Trauma Centers
5.4.3 Retail Pharmacies
5.4.4 Ambulatory Surgery Centers
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Alexion Pharmaceuticals Inc.
6.3.2 CSL Behring
6.3.3 Pfizer Inc.
6.3.4 AstraZeneca
6.3.5 Octapharma AG
6.3.6 Boehringer Ingelheim
6.3.7 Fresenius Kabi
6.3.8 Bausch Health
6.3.9 Amneal Pharmaceuticals
6.3.10 Ferring Pharmaceuticals
6.3.11 Baxter International
6.3.12 Johnson & Johnson (Ethicon)
6.3.13 Perosphere Pharma
6.3.14 Nichi-Iko Pharma
6.3.15 Grifols S.A.
6.3.16 Sanquin Blood Supply Foundation
6.3.17 Octava Pharma USA (Balfaxar)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security